This week Apple announced that researchers and app developers can now have access to a Health Record API (Application Programming Interface) to develop applications, with the permission to use the patient’s data to provide them with easy access to health records.
Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
Updated clinical data on its T-cell therapies has been presented by Adaptimmune. The GlaxoSmithKline-partnered NY-ESO SPEAR T-cells have been linked by the latest readouts to a 50% partial response rate in heavily pretreated cancer patients and have led to the positioning of Adaptimmune for dialing up of dosing of two wholly owned assets.
The New York-based startup is aiming to digitize the equipment and to make the process easier through the ePrescribing platform. That way, the hospital doesn't spend time on faxing to communicate the order, and the patients and healthcare suppliers can get it quicker than they might have otherwise.
On Sunday, at the American Society of Clinical Oncology’s annual meeting, Novartis revealed the final outcome, showing that among patients with HR-positive, HER2-negative breast cancer, adding Kisqali to fulvestrant kept the disease away for eight months longer than fulvestrant alone.
Yesterday, Apple announced that they are planning to introduce new features for iPhone and iPads called “Digital health” on this coming Monday (4th June 2018) at WWDC 2018- Apple Worldwide Developer Conference.
Los Angeles-based Cedars –Sinai Medical center and UCLA experimenters are describing that a (consumer-grade) Fitbit tracker can be used in some Remote patient Monitoring programs if health professionals know the clinical limitation of the mobile health wearables. The researchers outlined the 90-day study and concluded that the Fitbit data could be used to identify trends that call for health professional involvement
The company also announced that it service has recorded 10,000 pregnancies amongst its users. Ava launched its first wearable in 2016 and announced that the bracelet can detect a new pregnancy. Although it can be also be used to evade pregnancy.
The global biopharmaceutical company revealed its proposal for the new facility two years back when it signed its agreement with German-based construction engineering company M+W, the plant is expected to be 320,000 square feet. The factory will employee about 900 people, which is scheduled to operate in full- fledge by the first half of 2020.
A startup company called Nanochon secure 1st place at the 3DHEALS conference this year after delivering its pitch to a group of investors including Asimov Ventures, GE Ventures, Digital Industrialist.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.